Metabolic-associated steatohepatitis (MASH) is an advanced and progressive liver disease that potentially causes cirrhosis ...

Prime Day has no shortage of great deals on both LEGO sets and popular board games. But what if I told you you can get both ...

For decades, MASH has reigned as one of the smartest, most heartfelt, and downright funniest wartime comedy series of all ...

Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

"We’re helping hip-hop and classical music grow and expand beyond their boundaries," Cypress Hill's "Sen Dog" says.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...